The web Browser you are currently using is unsupported, and some features of this site may not work as intended. Please update to a modern browser such as Chrome, Firefox or Edge to experience all features Michigan.gov has to offer.
News and Announcements
News and Announcements
News and Announcements
MDHHS Awards $400,000 to Expand, Improve Sickle Cell Care | May 2026
The Michigan Department of Health and Human Services (MDHHS) has awarded nearly $400,000 in grants to support five projects aimed at improving access to quality care for individuals living with sickle cell disease (SCD). The funded projects align with Michigan’s 2026-2030 SCD Public Health Strategic Plan and focus on offering resources to providers that can help increase patient access to quality, integrated health care and the use of disease-modifying therapies, as well as improve acute care services delivered to patients living with SCD.
To read the full press release and learn more about the funded grantees, visit go.mi.gov/ozwsu2608.
MDHHS Releases their Sickle Cell Disease (SCD) Strategic Plan | February 2026
The Michigan Department of Health and Human Services (MDHHS) participated in SCD awareness events across the state, shared educational content on social media and published several reports about Michigan residents living with SCD. Building on these efforts, the Department is renewing its commitment to improving care, support, education and health outcomes for individuals living with SCD. The voices of individuals with SCD, their families and caregivers are central to the efforts underway and the updated strategic plan development. Through collaborative discussions with individuals living with SCD, their caregivers, healthcare providers, advocacy organizations, and community partners, MDHHS has identified six strategic goals to guide continued progress.
For more information on the plan visit, Michigan.gov/sicklecell.
MDHHS Joins CMS Cell & Gene Therapy Access Model to Expand Access to Innovative Treatments | February 2026
The Michigan Department of Health and Human Services (MDHHS) has elected to participate in the Centers for Medicare & Medicaid Services (CMS) Cell & Gene Therapy Access Model, a groundbreaking initiative designed to improve access to FDA-approved cell and gene therapies through outcomes-based payment arrangements. Key Highlights of the Model: Collaborative Approach: Brings CMS, states, and drug manufacturers together to improve access to high-cost, innovative therapies. CMS Negotiated Contracts: CMS negotiates agreements with pharmaceutical manufacturers on behalf of states. Contracts include standardized access policies and pricing structures. Rebates and price concessions are tied to patient outcomes.
For more information on the model, visit cms.gov/priorities/innovation/innovation-models/cgt.